



## FDA-approved small-molecule kinase inhibitors

Wu, Peng; Nielsen, Thomas E.; Clausen, Mads Hartvig

*Published in:*  
Trends in Pharmacological Sciences

*Link to article, DOI:*  
[10.1016/j.tips.2015.04.005](https://doi.org/10.1016/j.tips.2015.04.005)

*Publication date:*  
2015

*Document Version*  
Peer reviewed version

[Link back to DTU Orbit](#)

*Citation (APA):*  
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015). FDA-approved small-molecule kinase inhibitors. *Trends in Pharmacological Sciences*, 36(7), 422-439. <https://doi.org/10.1016/j.tips.2015.04.005>

---

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **FDA Approved Small Molecule Kinase Inhibitors**

2 Peng Wu<sup>1</sup>, Thomas E. Nielsen<sup>2</sup>, and Mads H. Clausen<sup>1,3</sup>

3 <sup>1</sup> Department of Chemistry, Technical University of Denmark, Kgs. Lyngby DK-2800, Denmark

4 <sup>2</sup> Protein and Peptide Chemistry, Novo Nordisk A/S, Måløv DK-2760, Denmark

5 <sup>3</sup> Center for Nanomedicine and Theranostics, Technical University of Denmark, Kgs. Lyngby DK-  
6 2800, Denmark

7

8 Corresponding author: Peng Wu (penwu@kemi.dtu.dk)

1 **Abstract:**

2 Kinases have emerged as one of the most intensively pursued targets in current pharmacological  
3 research, especially for cancer, due to their critical roles in cellular signaling. To date, the USA  
4 Food and Drug Administration (FDA) has approved twenty-eight small molecule kinase inhibitors,  
5 half of which were approved in the past three years. While the clinical data of these approved  
6 molecules are widely presented and structure-activity relationship (SAR) has been reported for  
7 individual molecules, an updated review that analyzes all approved molecules and summarizes  
8 current achievements and trends in the field has yet to be found. Herein we present all approved  
9 small molecule kinase inhibitors with an emphasis on binding mechanism and structural features,  
10 summarize current challenges, and discuss future directions in this field.

11

12 **Keywords:**

13 cancer, protein kinase, lipid kinase, tyrosine kinase, serine/threonine kinase, crystal structure

## 1 **Kinase inhibitors: A burgeoning field**

2 The past one and half decades witnessed an unparalleled success in the development of  
3 therapeutically useful kinase inhibitors, powered by tremendous progress in both academic and  
4 industrial settings. The milestone approval of the first kinase inhibitor, imatinib, in 2001 by FDA,  
5 was followed by a slow, yet steady approval of kinase inhibitors in the first ten years of this  
6 century with almost one new approval per year on average. Concurrently, our understanding of  
7 kinase signaling networks and disease pathology steadily grew, culminating in the approval of  
8 fifteen new small molecule kinase inhibitors from January 2012 to February 2015 - an unparalleled  
9 achievement in the history of pharmaceutical research. As of March 2015, a total of twenty-eight  
10 small molecule kinase inhibitors have been approved along with a large number of other  
11 compounds currently being evaluated in clinical and preclinical trials. In addition, more than one  
12 million publications on kinases have been released, more than five thousand crystal structures of  
13 kinases with or without small molecules have been solved, inhibition assays have been developed  
14 for more than four-fifths of the human kinome, and small molecule kinase inhibitors have been  
15 identified for about one-fifth of the human kinome. All these facts reflect the surging interest in  
16 this field. Thus, it is now safe to state that the development of small molecule kinase inhibitors has  
17 emerged as one of the most extensively pursued areas of drug discovery. In spite the abundance  
18 of data, common binding modes and structural features of approved small molecule kinase  
19 inhibitors are rarely reported in a systematic way that is easily accessible. Instead, information on  
20 individual inhibitors and their analogues appears scattered and fragmented. In this review, we  
21 provide a comprehensive overview and discuss the function mechanism and structural binding  
22 features of approved small molecule kinase inhibitors based on co-crystal structures. With the  
23 notion that fifteen kinase inhibitors were approved by FDA in the short period from 2012 to

1 February 2015, emphasis will be put on those small molecules, for which few SAR discussions have  
2 been presented. The intention of this review is to compile structural and binding information  
3 useful for the discovery of new kinase inhibitors, summarize current limitations and challenges,  
4 and propose future directions in the field in light of the most successful design-to-approval  
5 examples.

## 6 **Kinases**

7 Kinases catalyze the transfer of the  $\gamma$ -phosphate group of ATP onto a substrate, mediate most  
8 signal transductions [1], and regulate various cellular activities, including proliferation, survival,  
9 apoptosis, metabolism, transcription, differentiation, and a wide array of other cellular processes  
10 [2]. Accumulating pharmacological and pathological evidence have revealed that kinases are  
11 promising drug targets for the treatment of numerous diseases [3], such as cancers [4-6],  
12 inflammatory diseases [7, 8], central nervous system (CNS) disorders [9], cardiovascular diseases  
13 [10], and complications of diabetes [11].

14 Pioneering studies on the characterization of the phosphorylase kinase in the 1950s [12-14], and  
15 the identification of the first kinase signaling cascade involving protein kinase A (PKA) in 1968 [15],  
16 constituted the first few pieces of the jigsaw puzzle of kinase cascades. The “decade of protein  
17 kinase cascades” in 1990s witnessed the unfolding of the mitogen-activated protein  
18 kinases/extracellular signal-regulated kinases (MARK/ERK, also known as Ras-Raf-MEK-ERK)  
19 pathway, the Janus kinases (JAK) pathway, and the phosphoinositide 3-kinase (PI3K) pathway [16,  
20 17]. So far, 518 human kinases and more than 900 genes encoding proteins with kinase activity  
21 have been confirmed [18, 19]. Albeit accounting for only about 5% of the total number of protein-

1 coding genes [20], kinases comprise one of the largest classes of proteins encoded by the human  
2 genome.

### 3 **Kinase inhibitors**

4 Although diverse in primary amino acid sequence, the human kinases share a great degree of  
5 similarity in their three-dimensional structures, especially in their catalytically active kinase  
6 domain where the ATP binding pocket is located: a  $\beta$ -sheet containing N-terminal lobe (N-lobe),  $\alpha$ -  
7 helix dominated C-terminal lobe (C-lobe), and a connecting hinge region [21]. ATP binds in the  
8 cleft formed between the N- and C-lobes and most kinase inhibitors perturb binding through  
9 interactions with this region. A flexible activation loop starting with a conserved amino acid  
10 sequence Asp-Phe-Gly (DFG) controls access to the active site [22] (Figure 1A). Categorized by  
11 binding modes, kinase inhibitors can be grouped into two classes: irreversible and reversible  
12 inhibitors. The former tend to covalently bind with a reactive nucleophilic cysteine residue  
13 proximal to the ATP binding site, resulting in the blockage of the ATP site and irreversible  
14 inhibition. The latter can be further classified into four main types based on the conformation of  
15 binding pocket and the DFG motif [23, 24] (Figure 1B). Type I inhibitors are ATP competitive  
16 inhibitors that bind to the active forms of kinases with the aspartate residue of the DFG motif  
17 facing into the active site of the kinase. Type II inhibitors bind to the inactive forms of kinase with  
18 the aspartate residue of the DFG motif protruding outwards from the ATP binding site of the  
19 kinase. Many type II inhibitors exploit specific pockets accessible in a region adjacent to the ATP  
20 binding site due to the rotation of the DFG motif. In the type III binding mode, inhibitors bind  
21 exclusively in an allosteric pocket adjacent to ATP without making any interaction with the ATP  
22 binding pocket. Type IV inhibitors bind to an allosteric site remote from the ATP binding pocket

1 [25]. Besides, some kinase inhibitors, such as bisubstrate and bivalent inhibitors (Type V) [26],  
2 exhibit more than one of the above-mentioned binding modes.

3 Small molecule kinase inhibitors are useful reagents to investigate and elucidate kinase  
4 functions in various cellular activities [5]. The dominant dogma that the kinase domain was too  
5 conserved to enable the selective inhibition by small molecules was challenged in the late 1980s  
6 when the first examples of selective kinase inhibitors against the epidermal growth factor receptor  
7 (EGFR) were reported [27, 28]. Since then, a large number of kinase inhibitors of various structural  
8 features and inhibition profiles have been identified aided by the deepening understanding of  
9 structural biology [3], especially the kinase/inhibitor binding complex elucidated by high resolution  
10 X-ray crystallography [29, 30].

11 Among the 28 clinically approved kinase inhibitors, most are tyrosine kinase inhibitors [31], few  
12 are serine/threonine kinase inhibitors, and one, idelalisib, is a lipid kinase inhibitor that was  
13 approved in Jul., 2014 (Figure 2). Judged by different binding modes, 26 are reversible inhibitors,  
14 and the remaining two, afatinib and ibrutinib, are irreversible inhibitors. Despite several promising  
15 allosteric kinase inhibitors being currently in clinical trials at different stages, trametinib is the only  
16 type III inhibitor approved so far. In this review, approved small molecule kinase inhibitors are  
17 discussed and grouped into different classes based on their binding modes and targets.

## 18 **Approved tyrosine kinase inhibitors**

### 19 *Reversible non-receptor tyrosine kinase (NRTK) inhibitors*

20 BCR-Abl was the first kinase for which a small molecule inhibitor was successfully approved [32].

21 On another note, being the first approved kinase inhibitor and a revolutionary success for the

1 treatment of chronic myeloid leukemia (CML) [17], imatinib has been the subject of various SAR  
2 studies to guide the design of next-generation inhibitors and provide a deeper understanding of  
3 the inhibition mechanism. Considerable efforts seek to develop inhibitors based on structural  
4 features derived from imatinib and its binding mode with BCR-Abl [33, 34]. Five BCR-Abl inhibitors  
5 have been approved so far: imatinib (Gleevec<sup>®</sup>, Novartis), dasatinib (Sprycel<sup>®</sup>, Bristol-Myers-  
6 Squibbs), nilotinib (Tasigna<sup>®</sup>, Novartis), Bosutinib (Bosulif<sup>®</sup>, Wyeth), and Ponatinib (Iclusig<sup>®</sup>, Ariad  
7 Pharm.).

8 Imatinib, nilotinib, and ponatinib bind with inactive BCR-Abl with the DFG-motif adopting an  
9 “out” conformation, utilizing three binding pockets (Figure 3). The pyridine-pyrimidine moiety of  
10 imatinib forms a conserved hydrogen bond with hinge residue Met318. The tolyl group occupies a  
11 hydrophobic pocket, and the amino group of the tolylaminopyrimidine moiety forms a hydrogen  
12 bond with the gate-keeper residue Thr315. The terminal piperazinylphenyl group binds inside an  
13 allosteric pocket, formed due to the flipped conformation of the DFG motif, where the piperazinyl  
14 amine forms bidentate ionic interactions with His361 and Ile360. Besides, hydrogen bonds are  
15 formed between the amide connecting link and Glu286, Asp 381 [35] (Figure 3A and 3B). In spite  
16 of high efficacy and limited toxicity in comparison with traditional chemotherapy drugs, point  
17 mutations in the kinases domain of BCR-Abl led to the development of drug resistance against  
18 imatinib [36, 37]. Thus, nilotinib was developed as a second-line therapy for CML that is imatinib-  
19 resistant due to point mutations on BCR-Abl, including E255V, M351T, and F486S. Nilotinib shares  
20 the same pyridine-pyrimidine-aminotolyl moiety with imatinib, the difference being the long chain  
21 binding within the allosteric pocket. The imidazole-phenyl moiety and the attached  
22 trifluoromethyl group make it possible for nilotinib to bind deeper and tighter within the allosteric  
23 pocket (Figure 3C and 3D). Nilotinib is potent against most mutations but not the common



1 gatekeeper mutation T315I which blocks the binding into the allosteric pocket due to mutation of  
2 the small threonine residue to a bulky isoleucine residue. In this context, ponatinib was developed  
3 as a new BCR-Abl inhibitor that exhibits potent T315I inhibitory activity. Instead of having a  
4 pyrimidineamino linker interacting with the gatekeeper residue Thr315, a slim alkyne linker that  
5 overcomes steric hindrance due to mutation of the gate-keeper residue was incorporated in  
6 ponatinib. Besides, ponatinib bears the piperizinyphenyl group of imatinib and the trifluoromethyl  
7 group of nilotinib, resulting in a more compact interaction with the allosteric pocket (Figure 3E and  
8 3F).

9 Dasatinib and Bosutinib are the two approved inhibitors that bind with the active conformation  
10 of BCR-Abl with the activation loop fully extended for substrate binding. As for dasatinib (Figure  
11 4A), the nitrogen of the thiazole core and the attached amino group form hydrogen bonds with  
12 hinge residue Met318. The long hydroxyethylpiperazinyl tail is exposed to the solvent region. The  
13 terminal toluidine group points towards a hydrophobic pocket close to the gatekeeper residue  
14 Thr315, which interacts with the connecting amide link through a hydrogen bond (Figure 4B and  
15 4C). Thus, T315I mutation related drug resistance also occurs in patients treated with dasatinib. In  
16 contrast to the other four approved BCR-Abl molecules, bosutinib bears an anilinequinoline core  
17 that is similar to the anilinequinazoline core of some EGFR inhibitors (Figure 4D). A hinge hydrogen  
18 bond is formed between the quinoline nitrogen and the backbone amide of Met 318. The  
19 substituted aniline group occupies the hydrophobic pocket adjacent to Thr315. The nitrile group  
20 extends into another Thr315-adjacent pocket, which may host water molecules to form conserved  
21 water-mediated hydrogen bond interactions with small molecule inhibitors to contribute to kinase  
22 selectivity [38]. Due to the propensity of BCR-Abl to adopt a certain conformation at low pH values  
23 needed for crystallization, the DFG-motif of the bosutinib-Abl complex exhibits a different

1 conformation from that of dasatinib-Abl complex (Figure 4E and 4F). While a bosutinib-Src  
2 complex with the DFG-motif adopts the same conformation as shown in the dasatinib-Abl complex  
3 has been reported recently [38].

4 Janus kinases (JAKs) are a family of intracellular NRTKs that are required for multiple signaling  
5 pathways initiated by cytokines and growth factor receptors to phosphorylate Signal Transducers  
6 and Activators of Transcription (STAT) proteins [39, 40]. Four isomers, JAK1, JAK2, JAK3 and  
7 Tyrosine kinase 2 (TYK2) have been identified as JAK family kinases. JAK3 is exclusively expressed  
8 in cells of the lymphoid lineage and plays important roles in the immune system [41], while the  
9 other three isoforms are ubiquitously expressed and regulate a range of physiological functions  
10 [42]. Although small molecule kinase inhibitors against JAKs are potential agents for the treatment  
11 of autoimmune and neoplastic disorders [43], the development of isoform-selective JAK inhibitor  
12 is challenging due to the high sequence similarity among the four JAK kinases [7].

13 Ruxolitinib (Jakafi<sup>®</sup>, Incyte Corp.) was the first approved JAK inhibitor (Figure 5A). It inhibits both  
14 JAK1 and JAK2 and is used for the treatment of myeloproliferative disorders, such as myelofibrosis.  
15 Tofacitinib (Xeljanz<sup>®</sup>, Pfizer) was approved by FDA as a JAK3 selective inhibitor in 2012 for the  
16 treatment of rheumatoid arthritis (Figure 5B). However, the efficacy of tofacitinib has been  
17 hindered by side effects, such as anemia and neutropenia, probably due to undesirable pan-JAK  
18 inhibition, thus it was not approved by European regulatory agencies. Both molecules bear a  
19 pyrrolo[2,3-*d*]pyrimidine scaffold, and whereas no co-crystal structure of ruxolitinib with JAK  
20 kinase has been published yet, crystal complexes of tofacitinib with JAK1, JAK2, and JAK3 are  
21 readily available [44, 45]. Tofacitinib binds within the ATP pocket of JAKs. The pyrrolo[2,3-*d*]  
22 pyrimidine scaffold forms two hydrogen bonds with hinge residues Leu905 and Glu903 in JAK3

1 (Leu932 and Glu930 in JAK2). The terminal cyanoacetyl handle extends into a cleft underneath the  
2 P-loop in the N-lobe. The methyl group of the piperidine ring occupies a small hydrophobic pocket  
3 in the C-lobe (Figure 5C and 5D). Compounds with better selectivity towards JAK3 and reduced  
4 side effects are currently being investigated as the next generation JAK inhibitors [46, 47].

#### 5 *Reversible receptor tyrosine kinase (RTK) inhibitors*

6 ErbB, named for their homology to the erythroblastoma viral gene product *v-ErbB*, is a family of  
7 RTKs that includes four members, ErbB1/epidermal growth factor receptor (EGFR), ErbB2/human  
8 epidermal growth factor receptor 2 (Her2), ErbB3/Her3, and ErbB4/Her4 [48]. The ErbB cascade is  
9 one of the most extensively studied signaling transduction pathways [49, 50], and the ErbB  
10 inhibitors gefitinib (Iressa<sup>®</sup>, AstraZeneca), erlotinib (Tarceva<sup>®</sup>, OSI Pharm.), lapatinib (Tykerb<sup>®</sup>,  
11 GlaxoSmithKline), vandetanib (Caprelsa<sup>®</sup>, AstraZeneca), and afatinib (Gilotrif<sup>®</sup>, Boehringer  
12 Ingelheim) constitute one of the largest groups of approved small molecule kinase inhibitors. All  
13 five inhibitors bear a common quinazoline scaffold occupying the ATP adenine binding pocket, a 4-  
14 amino substituent binding in a hydrophobic pocket close to the kinase hinge, and a long chain in  
15 the 6- and/or 7-position extending towards solvent to increase the overall solubility of the  
16 molecule. In contrast to the other four reversible inhibitors, afatinib bears an enone moiety in the  
17 long solubilizing chain, enabling it to form a covalent bond. Thus, afatinib will be discussed  
18 together with ibrutinib in the section for covalent inhibitors.

19 A complex of wild type EGFR with gefitinib was first reported in 2007 [51] (Figure 6A and 6B).  
20 Structures of EGFR kinases with mutations at L858R or T790M have also been solved by several  
21 different groups. Extensive efforts to crystallize drug-resistant double mutant L858R+T790M EGFR  
22 failed to give diffraction-quality crystals, until a structure of EGFR with L858R+T790M+V948R

1 mutations was recently co-crystalized with gefitinib [52] (Figure 6C). In contrast to the wild type  
2 EGFR conformation that showed an active state with Leu858 buried in the kinase N-lobe, this  
3 mutant EGFR structure adopted an inactive-like state where Arg858 residue is exposed to the  
4 solvent front. Although gefitinib, erlotinib and vandetanib are the few inhibitors for which no  
5 experimental evidence regarding inactive state recognition has been collected so far, this gefitinib-  
6 mutant EGFR co-crystal structure showed that maybe there is no structural hindrance for these  
7 inhibitors to bind with the inactive form of EGFR. SAR and structural features obtained from these  
8 mutant kinase complexes provide a new dimension for the development of kinase inhibitors that  
9 may better address challenging issues regarding selectivity and drug-resistance. Due to the high  
10 structural similarity, the erlotinib-EGFR complex showed the same binding mode with that of  
11 gefitinib-EGFR complex, albeit with different 6,7-quinazoline substituents exposed in the solvent  
12 region [53] (Figure 6D-6F).

13 Lapatinib is a dual EGFR and ErbB2 inhibitor. In contrast to the type I binding mode as shown for  
14 erlotinib and gefitinib, lapatinib binds with the inactive conformation of EGFR, utilizing not only  
15 the adenine pocket and the specific hydrophobic pocket, but also an allosteric pocket formed due  
16 to the conformation change of the DFG-motif [54] (Figure 6G, 6H). Equivalent to its binding with  
17 EGFR, lapatinib binds with the inactive conformation of ErbB4, which shares the same lapatinib-  
18 contacting residues with ErbB2 [55] (Figure 6I). Although it has been assumed that allosteric  
19 modulators like type II inhibitors may achieve higher selectivity in comparison with type I  
20 inhibitors due to the utilization of an allosteric pocket unfolded through the conformational  
21 change[56], some of the currently available allosteric inhibitors are highly nonselective and a  
22 recent binding mode analysis suggested that type II inhibitors do not show an intrinsic selectivity  
23 advantage over type I inhibitors [57].

1 Vandetanib is a multiple kinase inhibitor against EGFR, vascular endothelial growth factor  
2 (VEGFR), and RET [58]. Despite the absence of a vandetanib-EGFR complex, a co-crystal structure  
3 of vandetanib with RET of class XIV RTK showed the same type I binding as seen in gefitinib and  
4 erlotinib [58](Figure 6J-6L).

5 VEGFRs, comprised of three major isoforms, 1, 2, and 3, are receptors of vascular endothelial  
6 growth factor (VEGF) that is an important signaling protein in vasculogenesis and angiogenesis [59,  
7 60]. Like Bcr-Abl and EGFR, VEGFR is among the earliest and most extensively-studied kinases  
8 targeted by synthetic small molecules for cancer treatment. Seven approved small molecule  
9 inhibitors target VEGFR as their primary target: sorafenib (Nexavar<sup>®</sup>, Bayer), sunitinib (Sutent<sup>®</sup>,  
10 Pfizer), pazopanib (Votrient<sup>®</sup>, GlaxoSmithKline), axitinib (Inlyta<sup>®</sup>, Pfizer), regorafenib (Stivarga<sup>®</sup>,  
11 Bayer), nintedanib (Ofev<sup>®</sup>,Boehringer Ingelheim), and lenvatinib (Lenvima<sup>®</sup>, Eisai Inc.).

12 The binding mode of VEGFR with small molecule inhibitors has been the subjects of SAR  
13 discussions in many studies due to the early resolution of corresponding co-crystal structures.  
14 General binding mode and common structural features are shown based on the VEGFR2-  
15 complexes that are available for four of the seven approved VEGFR inhibitors [61] (Figure 7A-7H):  
16 the conserved hinge bond is formed between the picolinamide group of sorafenib with Cys919,  
17 the indolinone core of sunitinib with Glu917 and Cys919, the indazole core of axitinib with Glu917  
18 and Cys919, and the indolinone core of nintedanib with Glu917 and Cys919. Except for sunitinib,  
19 the allosteric pocket formed due to the relocation of the DFG group is utilized by the remaining  
20 three molecules: the terminal 4-chloro-3-(trifluoromethyl)phenyl group of sorafenib binds in a  
21 deep hydrophobic allosteric pocket and the urea group lying in an allosteric channel forms  
22 hydrogen bonds with N-lobe residue Glu885 and the activation loop residue Asp 1046, axitinib

1 interacts with a small part of the allosteric pocket through its terminal benzamide group, and  
2 nintedanib binds with the allosteric pocket using its terminal methylcarboxy group. Another  
3 difference among these four compounds is the presence of a solubilizing chain: both sunitinib and  
4 nintedanib have a long terminal chain lying in the solvent region, axitinib's moderate-length  
5 pyridylvinyl chain extends to the solvent front, while sorafenib is basically buried inside the  
6 binding pocket without direct interaction with the solvent. In the case of nintedanib, ionic  
7 interactions are formed between the N-methylpiperazinyl group and Glu850. Regorafenib only  
8 differs from sorafenib by the presence of a fluorine atom (Figure 7I), thus similar type II binding  
9 with VEGFR2 as for sorafenib is expected. Both sorafenib and regorafenib are multi-target protein  
10 kinase inhibitors. Besides inhibition of VEGFR and B-raf, sorafenib has also been shown to be a  
11 potent low nanomolar inhibitor of p38 $\alpha$  through binding with its inactive conformation (3GCS, 2.1  
12 Å) [62]. A predicted type II binding mode of pazopanib with VEGFR2 is depicted (Figure 7J) based  
13 on a VEGFR2-complex with a similar indazolylpyrimidine-2,4-diamine compound that only differs  
14 in the aniline substituent at the 2-position of the pyrimidine-2,4-diamine [63]. Although a co-  
15 crystal structure of VEGFR2 with lenvatinib (PDB ID: 3WZD) has been reported in November 2014  
16 [64], for unspecified reasons, it is still not accessible through the PDB database. It was reported  
17 that lenvatinib binds into both the ATP binding site and a neighboring allosteric region of VEGFR2  
18 with the DFG motif adopting an "in" conformation (Figure 7K), making it an inhibitor that  
19 possesses both type I and II binding features [64].

20 Anaplastic lymphoma kinase (ALK) is a RTK that shares great sequence similarity to leukocyte  
21 tyrosine kinase (LTK) [65]. Chromosomal rearrangements in ALK have been detected in different  
22 types of human cancer, and together with other oncogenic evidence, ALK has been adopted as

1 another attractive target for cancer treatment with more than 10 molecules currently undergoing  
2 clinical trials [66].

3 Crizotinib (Xalkori<sup>®</sup>, Pfizer) was the first ALK inhibitor approved (Figure 8A), for the treatment of  
4 late stage lung cancer, anaplastic large cell lymphoma, and neuroblastoma. It was also the first  
5 drug specifically targeting NSCLC patients. Besides ALK, crizotinib also acts on ROS proto-oncogene  
6 1 encoded kinase (ROS1) of the tyrosine kinase insulin receptor class and MET proto-oncogene  
7 encoded kinase (MET) of the hepatocyte growth factor receptor (HGFR) class[67, 68]. A co-crystal  
8 structure with ALK showed that crizotinib binds with the ATP-binding pocket in a type I mode. The  
9 aminopyridine core sits at the adenine pocket and makes hydrogen bonds with hinge residues  
10 Glu1197 and Met1199. The methyl group of the benzyloxy moiety binds with a small hydrophobic  
11 pocket under the N-lobe. The 2,6-dichloro substituent of the terminal benzyl handle contributes to  
12 the high potency against c-MET. Overall, crizotinib does not fully utilize the structural features of  
13 the ATP binding pocket of ALK, which partially explained its poor selectivity [68] (Figure 8B, 8C).

14 Ceritinib (Zykadia<sup>®</sup>, Novartis) was developed as a second-generation ALK inhibitor for the  
15 treatment of non-small-cell lung carcinoma (NSCLC) with developed resistance to crizotinib due to  
16 rearrangements of the ALK gene[69] (Figure 8D). It has been shown that ceritinib potently  
17 overcomes ALK bearing L1196M, G1269A, I1171T, and S120Y mutations, but not ALK with G1202R  
18 and F1174C mutations [70]. ALK-ceritinib co-crystal structure showed a similar binding mode to  
19 that of ALK-crizotinib complex with the DFG motif adopting the “in” conformation [70]. The  
20 conserved hydrogen bonds were formed between the 2,4-diaminopyrimidine core and hinge  
21 residue Met1199. The isopropylsulfonylphenyl handle binds deeper inside the hydrophobic pocket,

1 and the anchor-shaped terminal 2-isopropoxy-3-(piperidin-4-yl)phenyl group lies in the interface  
2 between solvent and the ATP binding pocket.

3 MET, or c-MET, is a tyrosine kinase that is the only known receptor of HGF [71, 72]. MET induced  
4 activation of signaling cascade recruits downstream effectors including SRC, PI3K, tyrosine  
5 phosphatase SRC homology 2 domain-containing phosphatase 2 (SHP2), transcription factor signal  
6 transducer, and activator of transcription (STAT-3), regulating proliferation, motility, migration,  
7 and a wide range of other cellular activities [73]. Given its pivotal role in cancer development and  
8 progression, MET has been promoted as a versatile candidate for cancer treatment [74]. Besides a  
9 small group of selective MET inhibitors, most current MET inhibitors target multiple kinases,  
10 including the two approved molecules: above-mentioned crizotinib and the dual MET and VEGFR2  
11 inhibitor cabozantinib (Cometriq®, Exelixis). A recent study showed that cabozantinib overcomes  
12 crizotinib resistance stemming from acquired mutations in ROS1 [75].

13 MET-crizotinib complex showed a type I binding mode similar to that of the ALK-crizotinib  
14 complex with the DFG adopting an “in” conformation [68] (Figure 9A). The hinge hydrogen bonds  
15 involving the aminopyridine core are preserved, while the 3-fluoro-2,6-dichlorobenzyl moiety  
16 binds in a big hydrophilic pocket adjacent to the solvent front (Figure 9B, 9C). In spite of the  
17 absence of a MET co-crystal structure with cabozantinib (Figure 9D), the MET complex with  
18 compound DWF (Figure 9E), a closely related analogue, showed a potent type II binding mode. The  
19 aminopyrimidine core and the connecting fluorophenyl group lie in the adenine pocket and  
20 hydrophobic pocket utilized by crizotinib, respectively. The DFG-out conformation opens a  
21 hydrophobic allosteric pocket that is occupied by the terminal 4-fluorophenyl group. Besides  
22 forming a hydrogen bond with the N-lobe residue Lys1110, the cyclopropane-dicarboxamide link



1 binds with an allosteric channel interacting directly with the DFG residue Asp1222 through the  
2 formation of a hydrogen bond. The sulfonylphenyl group extends to the solvent and forms  
3 hydrogen bonds with C-lobe residues Asp1164 and Asn1167 (Figure 9F, 9G).

#### 4 **Approved irreversible protein kinase inhibitors**

5 The EGFR inhibitor afatinib was the first clinically approved irreversible kinase inhibitor, followed  
6 shortly by ibrutinib in November 2013. The approval of these two molecules validates the strategy  
7 of incorporating Michael acceptor functionality in small molecule inhibitors to form a covalent  
8 bond with a cysteine residue in the active site of kinases. This type of irreversible inhibitors is  
9 expected to achieve greater specificity and potency, although concerns have been raised regarding  
10 potential toxicities.

11 Co-crystal structures of both wild type EGFR-afatinib and mutant T790M EGFR-afatinib showed  
12 a type I binding mode that is in high degree of similarity with other approved reversible EGFR  
13 inhibitors sharing the same anilinoquinazoline core (Figure 10A). A conserved hydrogen bond is  
14 formed between hinge residue Met793 and the quinazoline ring. Electron density indicated that  
15 formation of a covalent C-S bond (1.8 Å) between the enone tail and Cys797 at the edge of the  
16 active site in the C-lobe [76] (Figure 10B, 10C).

17 Ibrutinib (Imbruvica®, Pharmacyclics Inc.) is a non-receptor tyrosine kinase inhibitor that targets  
18 Bruton's tyrosine kinase (BTK), which is an essential component of B-cell receptor signaling in  
19 regulating survival and proliferation of chronic lymphocytic leukemia (CLL) cells [77]. It was  
20 approved for the treatment of mantle cell lymphoma in November 2013, and then for CLL in  
21 February 2014 [78]. Global sales of Ibrutinib are expected to reach 9 billion US dollars in 2020 [79].  
22 A co-crystal structure of BTK with ibrutinib has yet to be reported, but one of BTK with a close

1 analogue of ibrutinib, B43, could be used to deduce a general binding mode between BTK and  
2 ibrutinib [80] (Figure 10D, 10E). B43 binds to the ATP site with the activation loop displaying a  
3 “DFG-in” conformation. The 4-amino pyrrolopyrimidine of B43 mimics the adenine ring of ATP,  
4 making several hydrogen bond interactions with the hinge region. The terminal phenyl group is  
5 twisted out of the connecting phenyl ether plane to enter a hydrophobic pocket mainly formed by  
6 the N-lobe residues. The phenoxyphenyl group forms  $\pi$ -stacking interactions with residues of this  
7 hydrophobic pocket. The cyclopentyl group of B43 extends towards Cys481 of the activation loop  
8 (Figure 10F). In the case of ibrutinib, the cyclopentyl group is replaced with an *N*-acryloylpiperidine  
9 group that acts as a Michael acceptor in reaction with the vicinal cysteine.

#### 10 **Approved serine/threonine kinase inhibitors**

11 Serine/threonine kinase B-Raf, one of the three isoforms of the Raf family, has been established as  
12 an attractive anticancer target [81]. Replacement of Val600 with Glu600 within the activation loop  
13 of the kinase domain accounts for 90% of B-Raf mutations [82], resulting in destabilization of the  
14 inactive conformation, elevated activation of the MAPK pathway, and enhanced promotion of cell  
15 survival and proliferation. Efforts in developing small molecule kinase inhibitors lend to the  
16 approved of the first B-Raf inhibitor Vemurafenib (Zelboraf<sup>®</sup>, Roche) in 2011 for the treatment of  
17 metastatic melanoma and thyroid tumors [81], followed by the approved of Dabrafenib (Tafinlar<sup>®</sup>,  
18 GlaxoSmithKline) in 2013. Besides, the tyrosine kinase inhibitor sorafenib has also been shown to  
19 inhibit Raf kinases including C-Raf and B-Raf [82].

20 Vemurafenib (Figure 11A) was developed using a fragment-based drug discovery strategy. The  
21 V600E B-Raf-vemurafenib co-crystal structure showed a type I binding mode. Vemurafenib  
22 occupies the ATP binding site with a DFG-in conformation, enabling the formation of hydrogen

1 bond interactions between the sulfonamide moiety and the DFG residues. Hydrogen bonds are  
2 also formed between the pyrrolopyridine core and hinge residue Cys532 and Gln530, mimicking  
3 that of the adenine core of ATP. The terminal 4-chlorophenyl group is exposed to the solvent front.  
4 Besides, an outward shift of the regulatory  $\alpha$ C-helix caused by vemurafenib binding to the kinase  
5 was observed [83] (Figure 11B, 11C). Although no co-crystal structure of dabrafenib (Figure 11D)  
6 with B-Raf has been obtained yet, a complex of mutant V600E B-Raf with compound **20** (Figure  
7 11E), a diarylthiazole derivate of dabrafenib, showed an interacting mode that shares features of  
8 type I binding. Compound **20** binds the ATP site with the activation loop adopting a DFG-in  
9 conformation. Hydrogen bond interactions with the hinge and the DFG residues were preserved  
10 through the acetamidopyridine handle and the sulfonamide moiety, respectively. The 2,5-  
11 difluorophenyl moiety extends inside a hydrophobic pocket, or Ras-selective pocket, which is  
12 formed through the outward movement of the  $\alpha$ C-helix. The thiazole core occupies the ribose  
13 pocket that is barely utilized by other kinase inhibitors, and the cyclopropylpiperidine tail attached  
14 to the thiazole core extends towards the solvent environment [84] (Figure 11F). A mechanistic  
15 study indicated that the activation loop of B-Raf is held in an inactive state by association with the  
16 P-loop. Mutations of the activation loop or the P-loop disrupt the inactive conformation and  
17 convert B-Raf into its active conformation. Co-crystal structure of tyrosine kinase inhibitor  
18 sorafenib with both wild type and mutant B-Raf showed different binding modes when the Val599  
19 of the activation loop is mutated to Glu599 [82] (Figure 11G-11I).

20 Along the MAPK pathway, MEK is another target for which a considerable number of small  
21 molecule inhibitors have been identified [85], including the only approved molecule trametinib  
22 (Mekinist<sup>®</sup>, GlaxoSmithKline) (Figure 12A). Trametinib was developed based on a high-throughput  
23 screening hit that bears the same pyridopyrimidinetrione core. SAR studies driven by growth

1 inhibitory activity against cancer cell lines lead to the discovery of trametinib [86], whose target  
2 was then confirmed as MEK1 and MEK2 guided by the structural features of known MEK inhibitors.  
3 The co-crystal structure of MEK1 with an analogue of trametinib, TAK-733 (Figure 12B), showed a  
4 type III binding mode. The pyridopyrimidinedione core lies in an allosteric pocket adjacent to the  
5 ATP binding pocket with the pyridine oxygen forming hydrogen bonds with Val211 and Ser212 and  
6 the pyrimidine oxygen interacting with Lys97. The 2-fluoro-4-iodoaniline moiety functions as a  
7 recognition motif for the hydrophobic pocket of the MEK allosteric site. The hydroxyl groups of the  
8 terminal dihydroxypropyl chain forms hydrogen bonds with both the ATP phosphate and Lys97 [87]  
9 (Figure 12C). A combination strategy of B-Raf inhibitor dabrafenib with MEK inhibitor trametinib,  
10 approved for the treatment of mutant V600E/K metastatic melanoma by FDA in early 2014, has  
11 been used to overcome drug resistance that occurs within about half a year after applying B-Raf  
12 inhibitors [88, 89].

13 Serine/threonine kinases Akt and mTOR of the PI3K/Akt/mTOR pathway are also promising  
14 targets [90]. Although no small molecule kinase inhibitors has been approved for either Akt or  
15 mTOR, a pipeline of candidates are currently undergoing various clinical trials in different phases  
16 [91]. For mTOR inhibitors, three natural-product-based macrolides, sirolimus, temsirolimus, and  
17 everolimus, were approved for clinical use in 1999, 2007, and 2009, respectively [90].

18 Cyclin-dependent kinases (CDKs) represent another group of serine/threonine kinases that have  
19 been studied as targets for therapeutic intervention in various types of cancers and other  
20 proliferative diseases [92]. Intensive efforts have been made in the past two decades to discover  
21 inhibitors with varied selectivity against the eleven isoforms of CDKs, resulting in the emergence of  
22 approximately twenty CDK inhibitors currently in various clinical trials [93]. Eventually, the first

1 CDK inhibitor palbociclib (Ibrane®, Pfizer) was approved in February 2015 inhibitor for the  
2 treatment of breast cancer.

3 Palbociclib is a selective CDK4 and CDK6 inhibitor (Figure 13A). Due to conformational difference  
4 in the hinge region of CDKs, the selectivity profiles of CDK inhibitors are closely connected with  
5 their binding orientations [94]. Co-crystal structure of palbociclib with CDK6 showed a tight  
6 binding mode, in which hydrogen bonds are formed between the hinge residue Val101 and the  
7 aminopyrimidine moiety and between the DFG residue Asp163 and the 6-acetyl group. The 5-  
8 methyl and 6-acetyl groups fully occupy a hydrophobic pocket in the back of the ATP binding site.  
9 The piperazinyipyridinylamino substituent at the 2-position of the pyrido[2,3-*d*]pyrimidinone core  
10 binds into a specificity pocket facing to the solvent front (Figure 13B, 13C). Overall, palbociclib  
11 binds tightly into CDK6 and adopts a comparatively rigid orientation in comparison with other pan-  
12 CDK inhibitor due to the above-mentioned binding features [94].

### 13 **Approved lipid kinase inhibitor**

14 Lipid kinases, such as phosphoinositide 3 kinases (PI3Ks), were discovered as early as the 1980s  
15 [95]. It has been convincingly established that activation and mutation of PI3Ks and other key  
16 components of this signaling pathway play key roles in various stages of tumor development [96].  
17 Considerable efforts from both academia and industry have been involved in the development of  
18 small molecule lipid kinases since 1980s, but the clinical success of these inhibitors has been  
19 minimal until the approval of the first lipid kinase inhibitor, idelalisib (Zydelig®, Gilead Sciences),  
20 for CLL in combination with monoclonal antibody rituximab in July 2014 [97]. The approval of  
21 idelalisib, together with the BTK inhibitor ibrutinib, provides encouraging transformation in the  
22 treatment of CLL [98].

1 Idelalisib is a PI3K $\delta$  inhibitor [99] (Figure 14A). The crystal complex of PI3K $\delta$  with idelalisib  
2 revealed a type II binding that is similar to that of another selective PI3K $\delta$  inhibitor PIK39 [100].  
3 Idelalisib adopts a propeller-shaped conformation with the DFG motif posing in an “out”  
4 conformation [101]. The 5-fluoroquinazolinone moiety squeezes into an induced hydrophobic  
5 specificity pocket. The ethyl group binds in a hydrophobic pocket and the phenyl group extends  
6 into a hydrophobic region that is close to the solvent front. The hinge hydrogen bond, which is a  
7 highly conserved feature for PI3K inhibition [102], is formed between Val828 and the purine  
8 moiety that occupies the adenine pocket [101] (Figure 14B, 14C). Except for being approved for  
9 CLL, idelalisib has also been granted accelerated approval for relapsed follicular B-cell non-Hodgkin  
10 lymphoma and relapsed small lymphocytic lymphoma [103, 104].

11 More than twenty other PI3K inhibitors, including single-isoform inhibitors, such as PI3K $\alpha$   
12 inhibitor buparlisib (phase III, Novartis), selective-isoform inhibitors, dual inhibitors of PI3K and  
13 mTOR, and pan class-I PI3K inhibitors, are in development for cancers and inflammatory diseases  
14 [102]. However, the clinical data accumulated so far suggest that PI3K inhibitors have limited  
15 single-agent activity [105], possibly due to negative feedback inhibition and the resulting  
16 reactivation of downstream receptor signaling [106, 107]. Thus, rational combination strategies  
17 using monoclonal antibodies, tyrosine kinase inhibitors, and serine/threonine kinase inhibitors are  
18 needed to assist the clinical usage of PI3K inhibitors.

### 19 **Limitations and challenges**

20 Kinase-based drug discovery has achieved dramatic progress in the past fifteen years. Although  
21 kinase inhibition stands for a young therapeutic strategy in comparison with other traditional  
22 tactics targeting G-protein-coupled receptors (GPCRs), membrane channels and transporters,

1 protease, etc., an analysis of FDA-approved cancer drugs since 1980s reveals that kinases have  
2 already taken over from G-protein-coupled receptor (GPCR) as the most sought-after cellular  
3 targets for cancer treatment [108]. Our analysis of all FDA-approved molecule kinase inhibitors  
4 with a focus on binding mechanism and structural features reveals some general conclusions that  
5 form the current landscape of developing kinase inhibitors and reflects a number of significant  
6 challenges in spite of achieved advances.

7 First, only a small subset of the human kinome has been studied. Most kinase inhibition efforts  
8 are limited to a select group of kinases that belong to the tyrosine kinase (TK) group, although  
9 promising results are emerging for inhibition of kinases in groups of tyrosine-kinase like (TKL),  
10 containing CDK, MAPK, GSK3 and CLK kinases (CMGC), containing PKA, PKG and PKC kinases (AGC),  
11 and containing the calcium/calmodulin-dependent protein kinases (CAMK) in recent years. This  
12 imbalance is clearly illustrated by the fact that inhibitors of three groups of tyrosine kinases, BCR-  
13 Abl, ErbBs, VEGFRs, account for eighteen of the twenty-seven approved protein kinase inhibitors.

14 Second, in contrast with protein kinase inhibitors, only one lipid kinase inhibitor is currently on  
15 the market. Even though lipid kinase inhibitors were reported as early as 1990s and a variety of  
16 clinical and pre-clinical lipid kinase inhibitors have been published [102], few have showed  
17 sufficient activity used in single-agent trials.

18 Third, despite the fact that kinases signaling cascade regulates diverse cellular activities related  
19 to inflammatory indications, CNS disorders, cardiovascular disease, diabetes, and others, in  
20 addition to cancer, most currently available inhibitors, including 26 out of the 28 approved kinase  
21 inhibitors, are developed mainly for cancer treatment.

22 Fourth, many of the current kinase inhibitors were designed based on previously approved  
23 compounds, as shown by the high structural similarity among approved ErbB inhibitors, e.g., five

1 ErbB inhibitors share the same 4-(arylamino)quinazoline core with different 6- and/or 7-  
2 substituents. Consequently, only a small subset of chemotypes are being investigated, which is  
3 clearly reflected by the limited number of moieties that are being incorporated in the approved  
4 molecules.

5 Fifth, most inhibitors function as reversible inhibitors binding in the ATP binding pocket and due  
6 to the high sequence similarity around the ATP binding pockets of kinases, it has been a daunting  
7 task to develop kinase inhibitors with potent inhibition against desirable targets and minimal  
8 interactions with off-targets.

9 Sixth, closely connected with the previous point, a large number of inhibitors interact with more  
10 than one target. In contrast, few absolute-selective inhibitors, which might be evaluated as dual or  
11 multiple target inhibitors if a more comprehensive screening assay was used [109], have been  
12 identified so far.

### 13 **Future directions**

14 Based on the current trends discussed above, some challenging questions that might serve as  
15 directions for future development of small molecule kinase inhibitors and push the boundary of  
16 the research in this field need to be addressed appropriately.

17 First, the fact that current kinase inhibitors focus only on a small subset of the human kinome  
18 indicates that many kinases are neglected. Thus, there is a need to develop tools and selective  
19 probes to uncover the functions of these unknown kinases [110], which might serve as new  
20 targets for small molecule inhibitors. It is encouraging to see the approval of a first inhibitor  
21 targeting certain kinases in the past three years, like trametinib as the first approved MEK inhibitor  
22 in 2013, ibrutinib as the first approved BTK inhibitor in 2013, and palbociclib as the first approved  
23 CDK inhibitor in 2015.



1 Second, although significant efforts have been devoted to the development of lipid kinase  
2 inhibitors, the progress achieved is not as obvious as for protein kinase inhibitors. The approval of  
3 the first and only lipid kinase inhibitor idelalisib in 2014 added support to the strategy of using  
4 lipid kinase inhibitors as anticancer agents, especially in combination with other cancer treatment  
5 agents and methods. Considering the pivotal roles of lipids kinases, such as PI3Ks, in cellular  
6 cascade, it is reasonable to expect research on small molecule lipid kinase inhibitors for indications  
7 including not only cancer but also inflammation, to be a promising direction in this field.

8 Third, except being utilized in the prevalent theme for cancer treatment, kinase inhibitors have  
9 great potential in the treatment of nonlethal chronic diseases, such as cardiovascular and CNS  
10 disorders. The successful approval of tofacitinib established the concept for the treatment of  
11 arthritis. Even for cancer treatment, more knowledge needs to be gained to further understand  
12 the multifaceted cancer biology.

13 Fourth, more pharmacophores need to be explored to diversify the scaffolds of kinase inhibitors.  
14 Most currently approved kinase inhibitors are discovered based on hits from high-throughput  
15 screening (HTS), while HTS is becoming increasingly less effective since most useful scaffolds have  
16 already been retrieved from available compound libraries. So there is an urgent need to diversify  
17 the molecules in compound library for screening. Natural products, which usually contain  
18 pharmacophores and scaffolds that are different from most synthetic kinase inhibitors, could be a  
19 useful source to inspire the construction of libraries with expanded structural diversity.

20 Fifth, despite the fact that most approved kinase inhibitors are type I and II reversible inhibitors,  
21 the success of afatinib and ibrutinib stand as strong stimulators to rekindle the idea of targeting  
22 kinases with irreversible inhibitors. On the other hand, type III and IV inhibitors might show

1 different efficacy and selectivity in comparison with type I and II inhibitors. In a word, novel  
2 mechanism of action needs to be explored.

3 Sixth, the selectivity issue of kinase inhibitors has always been a controversial area. Early  
4 promiscuous inhibitors, e.g. staurosporine, and later pan-selective inhibitors have functioned as  
5 useful tools in oncology. Highly selective kinase inhibitors were actively sought after until the  
6 recent theory that inhibitors with favorable selectivity or multi-target selectivity might be more  
7 suitable for cancer treatment becoming more and more widely accepted. It has become clear that  
8 kinase inhibitors do not have to be absolute-selective, a favorable selectivity profile is needed to  
9 balance efficacy and toxicity.

## 10 **Concluding remarks**

11 Groundbreaking understanding of cellular signaling cascades at the molecular level has led to  
12 major advances in kinase research over the past decades. The dramatic progress in applying the  
13 strategy of targeted kinase inhibition in the past fifteen years has been highlighted by the  
14 successful approval of no less than twenty-eight small molecule kinase inhibitors. An analysis  
15 based on co-crystal structures of all approved inhibitors with a focus on binding mechanism and  
16 structural features is presented herein to provide an updated overview of the achievements and  
17 shape current limitations and challenges in this rapidly evolving field. Future directions that may  
18 lead to the discovery of small molecule kinase inhibitors with novel function mechanisms, new  
19 therapeutic indications, distinct structures, and different selectivity and pharmacological profiles  
20 are also proposed. Although the current task of developing small molecule kinase inhibitors is  
21 highly interdisciplinary, the ultimate answer to the question of which type of kinase inhibitor is  
22 most useful will have to come from the accumulated clinical data of the approved molecules  
23 discussed in this review.

## 1 **Acknowledgement**

2 The Lundbeck Foundation (R140-2013-13835) is gratefully acknowledged for financial support. We  
3 thank Prof. David A. Tanner for proofreading of the manuscript.

## 4 **Supplementary data**

5 A poster with the generic name, commercial name, company, kinase target(s), chemical structure,  
6 first approval date, and clinical indication(s) of the twenty-eight FDA approved small molecule  
7 kinase inhibitors.

8

## 9 **References**

- 10 1 Johnson, L.N. and Lewis, R.J. (2001) Structural basis for control by phosphorylation. *Chem. Rev.*  
11 101, 2209-2242
- 12 2 Adams, J.A. (2001) Kinetic and catalytic mechanisms of protein kinases. *Chem. Rev.* 101, 2271-  
13 2290
- 14 3 Rask-Andersen, M., *et al.* (2014) Advances in kinase targeting: current clinical use and clinical  
15 trials. *Trends Pharmacol. Sci.* 35, 604-620
- 16 4 Huang, M., *et al.* (2014) Molecularly targeted cancer therapy: some lessons from the past  
17 decade. *Trends Pharmacol. Sci.* 35, 41-50
- 18 5 Ma, W.W. and Adjei, A.A. (2009) Novel agents on the horizon for cancer therapy. *CA Cancer J.*  
19 *Clin.* 59, 111-137
- 20 6 Sun, C. and Bernards, R. (2014) Feedback and redundancy in receptor tyrosine kinase signaling:  
21 relevance to cancer therapies. *Trends Biochem. Sci.* 39, 465-474

1 7 Clark, J.D., *et al.* (2014) Discovery and development of Janus Kinase (JAK) inhibitors for  
2 inflammatory diseases. *J. Med. Chem.* 57, 5023-5038

3 8 Barnes, P.J. (2013) New anti-inflammatory targets for chronic obstructive pulmonary disease.  
4 *Nat. Rev. Drug Discov.* 12, 543-559

5 9 Muth, F., *et al.* (2015) Tetra-substituted pyridinylimidazoles as dual inhibitors of p38 $\alpha$  mitogen-  
6 activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of  
7 neurodegenerative diseases. *J. Med. Chem.* 58, 443-456

8 10 Kikuchi, R., *et al.* (2014) An antiangiogenic isoform of VEGF-A contributes to impaired  
9 vascularization in peripheral artery disease. *Nat. Med.* 20, 1464-1471

10 11 Banks, A.S., *et al.* (2015) An ERK/Cdk5 axis controls the diabetogenic actions of PPAR $\gamma$ .  
11 *Nature* 517, 391-395

12 12 Burnett, G. and Kennedy, E.P. (1954) The enzymatic phosphorylation of proteins. *J. Biol. Chem.*  
13 211, 969-980

14 13 Fischer, E.H. and Krebs, E.G. (1955) Conversion of phosphorylase b to phosphorylase a in muscle  
15 extracts. *J. Biol. Chem.* 216, 121-132

16 14 Krebs, E.G. and Fischer, E.H. (1956) The phosphorylase b to a converting enzyme of rabbit  
17 skeletal muscle. *Biochim. Biophys. Acta* 20, 150-157

18 15 Walsh, D.A., *et al.* (1968) An adenosine 3',5'-monophosphate-dependant protein kinase from  
19 rabbit skeletal muscle. *J. Biol. Chem.* 243, 3763-3765

20 16 Cohen, P. (2002) The origins of protein phosphorylation. *Nat. Cell Biol.* 4, E127-E130

21 17 Steelman, L.S., *et al.* (2004) JAK//STAT, Raf//MEK//ERK, PI3K//Akt and BCR-ABL in cell cycle  
22 progression and leukemogenesis. *Leukemia* 18, 189-218

1 18 The UniProt Consortium (2013) Update on activities at the Universal Protein Resource (UniProt)  
2 in 2013. *Nucleic Acids Res.* 41, D43-D47

3 19 Manning, G., *et al.* (2002) The protein kinase complement of the human genome. *Science* 298,  
4 1912-1934

5 20 Pennisi, E. (2012) ENCODE project writes eulogy for junk DNA. *Science* 337, 1159-1161

6 21 Knighton, D., *et al.* (1991) Crystal structure of the catalytic subunit of cyclic adenosine  
7 monophosphate-dependent protein kinase. *Science* 253, 407-414

8 22 Tong, M. and Seeliger, M.A. (2015) Targeting conformational plasticity of protein kinases. *ACS*  
9 *Chem. Biol.* 10, 190-200

10 23 Noble, M.E.M., *et al.* (2004) Protein kinase inhibitors: insights into drug design from structure.  
11 *Science* 303, 1800-1805

12 24 Norman, R.A., *et al.* (2012) Structural approaches to obtain kinase selectivity. *Trends Pharmacol.*  
13 *Sci.* 33, 273-278

14 25 Cox, K.J., *et al.* (2010) Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent  
15 (type V) inhibitors of protein kinases. *Future Med. Chem.* 3, 29-43

16 26 Lamba, V. and Ghosh, I. (2012) New directions in targeting protein kinases: focusing upon true  
17 allosteric and bivalent inhibitors. *Curr. Pharm. Design* 18, 2936-2945

18 27 Yaish, P., *et al.* (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase  
19 inhibitors. *Science* 242, 933-935

20 28 Gazit, A., *et al.* (1989) Tyrphostins I: synthesis and biological activity of protein tyrosine kinase  
21 inhibitors. *J. Med. Chem.* 32, 2344-2352

22 29 Gavrin, L.K. and Saiah, E. (2013) Approaches to discover non-ATP site kinase inhibitors.  
23 *MedChemComm* 4, 41-51

1 30 Wang, Q., *et al.* (2014) Chapter two - a structural atlas of kinases inhibited by clinically  
2 approved drugs. In *Methods Enzymol.* (Kevan, M.S., ed), pp. 23-67, Academic Press

3 31 Levitzki, A. (2013) Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical  
4 performance. *Annu. Rev. Pharmacol. Toxicol.* 53, 161-185

5 32 Druker, B.J., *et al.* (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine  
6 kinase in chronic myeloid leukemia. *N. Eng. J. Med.* 344, 1031-1037

7 33 Panjarian, S., *et al.* (2013) Structure and dynamic regulation of abl kinases. *J. Biol. Chem.* 288,  
8 5443-5450

9 34 Winter, G.E., *et al.* (2012) Systems-pharmacology dissection of a drug synergy in imatinib-  
10 resistant CML. *Nat. Chem. Biol.* 8, 905-912

11 35 Nagar, B., *et al.* (2002) Crystal structures of the kinase domain of c-Abl in complex with the  
12 small molecule inhibitors PD173955 and imatinib (STI-571). *Cancer Res.* 62, 4236-4243

13 36 Lamontanara, A.J., *et al.* (2013) Mechanisms of resistance to BCR-ABL and other kinase  
14 inhibitors. *Biochim. Biophys. Acta* 1834, 1449-1459

15 37 Ma, L., *et al.* (2014) A therapeutically targetable mechanism of BCR-ABL-independent imatinib  
16 resistance in chronic myeloid leukemia. *Sci. Transl. Med.* 6, 252ra121

17 38 Levinson, N.M. and Boxer, S.G. (2014) A conserved water-mediated hydrogen bond network  
18 defines bosutinib's kinase selectivity. *Nat. Chem. Biol.* 10, 127-132

19 39 Xuan, Y.-T., *et al.* (2001) An essential role of the JAK-STAT pathway in ischemic preconditioning.  
20 *Proc. Natl. Acad. Sci. USA* 98, 9050-9055

21 40 Meyer, S.C. and Levine, R.L. (2014) Molecular pathways: molecular basis for sensitivity and  
22 resistance to JAK kinase inhibitors. *Clin. Cancer Res.* 20, 2051-2059

1 41 Divito, S.J. and Kupper, T.S. (2014) Inhibiting Janus kinases to treat alopecia areata. *Nat. Med.*  
2 20, 989-990

3 42 Doles, J.D. and Olwin, B.B. (2014) The impact of JAK-STAT signaling on muscle regeneration. *Nat.*  
4 *Med.* 20, 1094-1095

5 43 Geyer, H.L. and Mesa, R.A. (2014) Therapy for myeloproliferative neoplasms: when, which  
6 agent, and how? *Blood* 124, 3529-3537

7 44 Chrencik, J.E., *et al.* (2010) Structural and thermodynamic characterization of the TYK2 and  
8 JAK3 kinase domains in complex with CP-690550 and CMP-6 *J. Mol. Biol.* 400, 413-433

9 45 Williams, N.K., *et al.* (2009) Dissecting specificity in the Janus kinases: the structures of JAK-  
10 specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. *J. Mol. Biol.*  
11 387, 219-232

12 46 Goedken, E.R., *et al.* (2014) Tricyclic covalent inhibitors selectively target Jak3 through an  
13 active-site thiol. *J. Biol. Chem.*, doi:10.1074/jbc.M11114.595181

14 47 Gehringer, M., *et al.* (2014) Novel hinge-binding motifs for Janus Kinase 3 inhibitors: a  
15 comprehensive structure–activity relationship study on tofacitinib bioisosteres. *ChemMedChem* 9,  
16 2516-2527

17 48 Hynes, N.E. and Lane, H.A. (2005) ERBB receptors and cancer: the complexity of targeted  
18 inhibitors. *Nat. Rev. Cancer* 5, 341-354

19 49 Littlefield, P., *et al.* (2014) Structural analysis of the EGFR/HER3 heterodimer reveals the  
20 molecular basis for activating HER3 mutations. *Sci. Signal.* 7, ra114

21 50 Citri, A. and Yarden, Y. (2006) EGF–ERBB signalling: towards the systems level. *Nat. Rev. Mol.*  
22 *Cell Biol.* 7, 505-516

1 51 Yun, C.-H., *et al.* (2007) Structures of lung cancer-derived EGFR mutants and inhibitor  
2 complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell*  
3 11, 217-227

4 52 Gajiwala, Ketan S., *et al.* (2013) Insights into the aberrant activity of mutant EGFR kinase  
5 domain and drug recognition. *Structure* 21, 209-219

6 53 Stamos, J., *et al.* (2002) Structure of the epidermal growth factor receptor kinase domain alone  
7 and in complex with a 4-anilinoquinazoline inhibitor (Erlotinib with EGFR). *J. Biol. Chem.* 277,  
8 46265-46272

9 54 Wood, E.R., *et al.* (2004) A unique structure for epidermal growth factor receptor bound to  
10 GW572016 (lapatinib): relationships among protein conformation, Inhibitor off-rate, and receptor  
11 activity in tumor cells. *Cancer Res.* 64, 6652-6659

12 55 Qiu, C., *et al.* (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase.  
13 *Structure* 16, 460-467

14 56 Fang, Z., *et al.* (2013) Strategies for the selective regulation of kinases with allosteric  
15 modulators: exploiting exclusive structural features. *ACS Chem. Biol.* 8, 58-70

16 57 Zhao, Z., *et al.* (2014) Exploration of type II binding mode: a privileged approach for kinase  
17 inhibitor focused drug discovery? *ACS Chem. Biol.* 9, 1230-1241

18 58 Knowles, P.P., *et al.* (2006) Structure and chemical inhibition of the RET tyrosine kinase domain.  
19 *J. Biol. Chem.* 281, 33577-33587

20 59 Ferrara, N., *et al.* (2003) The biology of VEGF and its receptors. *Nat. Med.* 9, 669-676

21 60 Olofsson, B., *et al.* (1996) Vascular endothelial growth factor B, a novel growth factor for  
22 endothelial cells. *Proc. Natl. Acad. Sci. USA* 93, 2576-2581



1 61 McTigue, M., *et al.* (2012) Molecular conformations, interactions, and properties associated  
2 with drug efficiency and clinical performance among VEGFR TK inhibitors. *Proc. Natl. Acad. Sci.*  
3 *USA* 109, 18281-18289

4 62 Simard, J.R., *et al.* (2009) Development of a fluorescent-tagged kinase assay system for the  
5 detection and characterization of allosteric kinase inhibitors. *J. Am. Chem. Soc.* 131, 13286-13296

6 63 Harris, P.A., *et al.* (2008) Discovery of 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-  
7 pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular  
8 endothelial growth factor receptor inhibitor. *J. Med. Chem.* 51, 4632-4640

9 64 Okamoto, K., *et al.* (2015) Distinct binding mode of multikinase inhibitor lenvatinib revealed by  
10 biochemical characterization. *ACS Med. Chem. Lett.* 6, 89-94

11 65 Chiarle, R., *et al.* (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. *Nat.*  
12 *Rev. Cancer* 8, 11-23

13 66 Awad, M.M. and Shaw, A.T. (2014) ALK Inhibitors in non–small cell lung cancer: crizotinib and  
14 beyond. *Clin. Adv. Hematol. Oncol.* 12, 429-439

15 67 Awad, M.M., *et al.* (2013) Acquired resistance to crizotinib from a mutation in CD74–ROS1. *N.*  
16 *Eng. J. Med.* 368, 2395-2401

17 68 Cui, J.J., *et al.* (2011) Structure based drug design of crizotinib (PF-02341066), a potent and  
18 selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic  
19 lymphoma kinase (ALK). *J. Med. Chem.* 54, 6342-6363

20 69 Shaw, A.T., *et al.* (2014) Ceritinib in ALK-Rearranged non–small-cell lung cancer. *N. Eng. J. Med.*  
21 370, 1189-1197

22 70 Friboulet, L., *et al.* (2014) The ALK inhibitor ceritinib overcomes crizotinib resistance in non-  
23 small cell lung cancer *Cancer Discov.* 4, 662-673

1 71 Stamos, J., *et al.* (2004) Crystal structure of the HGF  $\beta$  - chain in complex with the Sema  
2 domain of the Met receptor. *EMBO J.* 23, 2325-2335

3 72 Basilico, C., *et al.* (2008) A High Affinity Hepatocyte Growth Factor-binding Site in the  
4 Immunoglobulin-like Region of Met. *J. Biol. Chem.* 283, 21267-21277

5 73 Trusolino, L., *et al.* (2010) MET signalling: principles and functions in development, organ  
6 regeneration and cancer. *Nat. Rev. Mol. Cell Biol.* 11, 834-848

7 74 Gelsomino, F., *et al.* (2014) MET and small-cell lung cancer. *Cancers* 6, 2100-2115

8 75 Katayama, R., *et al.* (2015) Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive  
9 cancer. *Clin. Cancer Res.* 21, 166-174

10 76 Solca, F., *et al.* (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an  
11 irreversible ErbB family blocker. *J. Pharmacol. Exp. Ther.* 343, 342-350

12 77 Hendriks, R.W., *et al.* (2014) Targeting Bruton's tyrosine kinase in B cell malignancies. *Nat. Rev.*  
13 *Cancer* 14, 219-232

14 78 Byrd, J.C., *et al.* (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *N.*  
15 *Eng. J. Med.* 369, 32-42

16 79 Garber, K. (2014) Kinase inhibitors overachieve in CLL. *Nat. Rev. Drug Discov.* 13, 162-164

17 80 Marcotte, D.J., *et al.* (2010) Structures of human Bruton's tyrosine kinase in active and inactive  
18 conformations suggest a mechanism of activation for TEC family kinases. *Protein Sci.* 19, 429-439

19 81 Bollag, G., *et al.* (2012) Vemurafenib: the first drug approved for BRAF-mutant cancer. *Nat. Rev.*  
20 *Drug Discov.* 11, 873-886

21 82 Wan, P.T.C., *et al.* (2004) Mechanism of activation of the RAF-ERK signaling pathway by  
22 oncogenic mutations of B-RAF. *Cell* 116, 855-867

1 83 Bollag, G., *et al.* (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-  
2 mutant melanoma. *Nature* 467, 596-599

3 84 Pulici, M., *et al.* (2014) Optimization of diarylthiazole B-Raf inhibitors: identification of a  
4 compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low  
5 paradoxical effect. *ChemMedChem* 10, 276-295

6 85 Luke, J.J., *et al.* (2014) The biology and clinical development of MEK inhibitors for cancer. *Drugs*  
7 74, 2111-2128

8 86 Abe, H., *et al.* (2011) Discovery of a highly potent and selective MEK inhibitor: GSK1120212  
9 (JTP-74057 DMSO solvate). *ACS Med. Chem. Lett.* 2, 320-324

10 87 Dong, Q., *et al.* (2011) Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor  
11 for the treatment of cancer. *Bioorg. Med. Chem. Lett.* 21, 1315-1319

12 88 Flaherty, K.T., *et al.* (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600  
13 mutations. *N. Eng. J. Med.* 367, 1694-1703

14 89 Long, G.V., *et al.* (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in  
15 melanoma. *N. Eng. J. Med.* 371, 1877-1888

16 90 Wu, P. and Hu, Y.Z. (2010) PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on  
17 clinical progress. *Curr. Med. Chem.* 17, 4326-4341

18 91 Chiarini, F., *et al.* (2015) Current treatment strategies for inhibiting mTOR in cancer. *Trends*  
19 *Pharmacol. Sci.* 36, 124-135

20 92 Choi, Y.J. and Anders, L. (2014) Signaling through cyclin D-dependent kinases. *Oncogene* 33,  
21 1890-1903

22 93 Casimiro, M.C., *et al.* (2014) Overview of cyclins D1 function in cancer and the CDK inhibitor  
23 landscape: past and present. *Expert Opin. Investig. Drugs* 23, 295-304

1 94 Lu, H. and Schulze-Gahmen, U. (2006) Toward understanding the structural basis of Cyclin-  
2 Dependent Kinase 6 specific inhibition. *J. Med. Chem.* 49, 3826-3831

3 95 Whitman, M., *et al.* (1985) Association of phosphatidylinositol kinase activity with polyoma  
4 middle-T competent for transformation. *Nature* 315, 239-242

5 96 Wu, P., *et al.* (2009) PI3K inhibitors for cancer therapy: what has been achieved so far? *Curr.*  
6 *Med. Chem.* 16, 916-930

7 97 Furman, R.R., *et al.* (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. *N.*  
8 *Eng. J. Med.* 370, 997-1007

9 98 Cheson, B.D. (2014) CLL and NHL: the end of chemotherapy? *Blood* 123, 3368-3370

10 99 Ali, K., *et al.* (2014) Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune  
11 tolerance to cancer. *Nature* 510, 407-411

12 100 Berndt, A., *et al.* (2010) The p110[delta] structure: mechanisms for selectivity and potency of  
13 new PI(3)K inhibitors. *Nat. Chem. Biol.* 6, 117-124

14 101 Somoza, J.R., *et al.* (2015) Structural, biochemical and biophysical characterization of Idelalisib  
15 binding to phosphoinositide 3-kinase delta. *J. Biol. Chem.*, doi: 10.1074/jbc.M1114.634683

16 102 Wu, P. and Hu, Y. (2012) Small molecules targeting phosphoinositide 3-kinases.  
17 *MedChemComm* 3, 1337-1355

18 103 Flinn, I.W., *et al.* (2014) Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase- $\delta$ , as  
19 therapy for previously treated indolent non-Hodgkin lymphoma. *Blood* 123, 3406-3413

20 104 Brown, J.R., *et al.* (2014) Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 $\delta$ , for  
21 relapsed/refractory chronic lymphocytic leukemia. *Blood* 123, 3390-3397

22 105 Fruman, D.A. and Rommel, C. (2014) PI3K and cancer: lessons, challenges and opportunities.  
23 *Nat. Rev. Drug Discov.* 13, 140-156

1 106 Costa, C., *et al.* (2015) Measurement of PIP3 levels reveals an unexpected role for p110 $\beta$  in  
2 early adaptive responses to p110 $\alpha$ -specific inhibitors in luminal breast cancer. *Cancer Cell* 27, 97-  
3 108

4 107 Schwartz, S., *et al.* (2015) Feedback suppression of PI3K $\alpha$  signaling in PTEN-mutated tumors is  
5 relieved by selective inhibition of PI3K $\beta$ . *Cancer Cell* 27, 109-122

6 108 Kinch, M.S. (2014) An analysis of FDA-approved drugs for oncology. *Drug Discov. Today* 19,  
7 1831-1835

8 109 Davis, M.I., *et al.* (2011) Comprehensive analysis of kinase inhibitor selectivity. *Nat. Biotech.*  
9 29, 1046-1051

10 110 Rask-Andersen, M., *et al.* (2014) The druggable genome: evaluation of drug targets in clinical  
11 trials suggests major shifts in molecular class and indication. *Annu. Rev. Pharmacol. Toxicol.* 54, 9-  
12 26

1 **Figure legend**

2 [Figure 1]

3 **Figure 1.** Kinase structure and different types of reversible small molecule kinase inhibitors. **(A)** Co-  
4 crystal structure of PDK1 with ATP (adenine and ribose in green backbone, phosphate groups in  
5 orange) with the enlarged area showing the structural elements around the ATP binding site.  
6 Hydrogen bonds in red dotted lines, hinge region and hinge residues in green backbone, P-loop  
7 and P-loop residue in brown orange backbone, the aspartate residue of the DFG motif and the  
8 activation loop in white backbone (PDB ID: 4RRV, 1.41 Å). **(B)** Four types of reversible binding  
9 modes: type I inhibitors bind to the active conformation of kinase with the aspartate residue  
10 (white backbone) of the DFG motif pointing into the ATP-binding pocket; type II inhibitors bind  
11 and stabilize the inactive conformation of kinase with the flipped aspartate residue facing outward  
12 of the binding pocket; type III inhibitors occupy an allosteric pocket that is adjacent to the ATP  
13 binding pocket but does not overlap with it; type IV inhibitors bind to an allosteric pocket remote  
14 from the ATP binding pocket.

15 [Figure 2]

16 **Figure 2.** FDA approved small molecule kinase inhibitors (as of March 2015).

17 [Figure 3]

18 **Figure 3.** Type II inhibitors of BCR-Abl. **(A)** Chemical structure of imatinib and its depicted binding  
19 mode with BCR-Abl. **(B)** Imatinib co-crystal structure (PDB ID: 1IEP, 2.10 Å). **(C)** Chemical structure  
20 of nilotinib and its depicted binding mode with BCR-Abl. **(D)** Nilotinib co-crystal structure (PDB ID:  
21 3CS9, 2.21 Å). **(E)** Chemical structure of ponatinib and its depicted binding mode with BCR-Abl. **(F)**

1 Ponatinib co-crystal structure with wild-type BCR-Abl (PDB ID: 3OXZ, 2.20 Å). Small molecule  
2 inhibitors are shown in magenta backbone, hydrogen bonds are indicated by red dotted lines, and  
3 residues that interact with inhibitors through hydrogen bonds are shown in green backbone, and  
4  $\pi$ -interactions formed between certain aromatic rings of these molecules and residues including  
5 Phe and Tyr are not illustrated in these ribbon-show figures. Co-crystal structures of ponatinib  
6 (PDB ID: 3IK3, 1.9 Å) and its analogue (PDB ID: 3OY3, 1.95 Å) with mutant T315I (shown in yellow  
7 backbone in F) BCR-Abl have also been released.

8 [Figure 4]

9 **Figure 4.** Inhibitors binding with active BCR-Abl. (A) Chemical structure of dasatinib and its  
10 depicted binding mode with BCR-Abl. (B) dasatinib co-crystal structure (PDB ID: 2GQG, 2.40 Å). (C)  
11 Surface show of the dasatinib-Abl co-crystal structure (PDB ID: 2GQG, 2.40 Å). (D) Chemical  
12 structure of bosutinib and its depicted binding mode with BCR-Abl. (E) Bosutinib co-crystal  
13 structure (PDB ID: 3UE4, 2.42 Å). (F) Surface show of the bosutinib-Abl co-crystal structure (PDB ID:  
14 2GQG, 2.40 Å). Small molecule inhibitors are shown in magenta backbone, hydrogen bonds are  
15 indicated by red dotted lines, residues that interact with inhibitors through hydrogen bonds are  
16 shown in green backbone, the gate-keeper residue is shown in yellow backbone, and residues of  
17 the DFG motif are shown in white backbones.

18 [Figure 5]

19 **Figure 5.** JAK inhibitors. (A) Chemical structure of ruxolitinib. (B) Chemical structure of tofacitinib  
20 and its depicted binding mode with JAK2/3. (C) Tofacitinib co-crystal structure with JAK3 (PDB ID:  
21 3LXK 2.0 Å). (D) Tofacitinib co-crystal structure with JAK2 (PDB ID: 3FUP 2.4 Å). Tofacitinib shown

1 in magenta backbone, hydrogen bonds are indicated by red dotted lines, and residues that  
2 interact with tofacitinib through hydrogen bonds are shown in green backbone.

3 [Figure 6]

4 **Figure 6.** Small molecule kinase inhibitors against ErbBs. **(A)** Chemical structure of gefitinib and its  
5 depicted binding mode with EGFR. **(B)** Gefitinib co-crystal structure with wild type EGFR (PDB ID:  
6 2ITY, 3.42 Å). **(C)** Gefitinib co-crystal structure with mutant L858R+T790M+V948R EGFR (PDB ID:  
7 4I22, 1.71 Å). **(D)** Chemical structure of erlotinib and its depicted binding mode with EGFR. **(E)**  
8 Erlotinib co-crystal structure with EGFR (PDB ID: 1M17, 2.60 Å). **(F)** Surface show of erlotinib co-  
9 crystal structure with EGFR (PDB ID: 1M17, 2.60 Å). **(G)** Chemical structure of lapatinib and its  
10 depicted binding mode with EGFR. **(H)** Lapatinib co-crystal structure with EGFR (PDB ID: 1XKK, 2.40  
11 Å). **(I)** Lapatinib-ErbB4 complex, the methylsulfonylethanylaminoethylfuranyl moiety is not  
12 shown in this crystal structure (PDB ID: 3BBT, 2.80 Å). **(J)** Chemical structure of vandetanib and its  
13 depicted binding mode with RET. **(K)** Vandetanib co-crystal structure with RET (PDB ID: 2IVU, 2.50  
14 Å). **(L)** Surface show of vandetanib co-crystal structure with RET (PDB ID: 2IVU, 2.50 Å). Small  
15 molecule inhibitors are shown in magenta backbone, hydrogen bonds are indicated by red dotted  
16 lines, residues that interact with inhibitors through hydrogen bonds are shown in green backbone,  
17 residue 858 and residue 790 in the gefitinib-EGFR complex are shown in yellow backbone, and  
18 residues of the DFG-motif are shown in white backbone.

19 [Figure 7]

20 **Figure 7.** Small molecule kinase inhibitors binding to VEGFR. **(A)** Chemical structure of sorafenib  
21 and its depicted binding mode with VEGFR2. **(B)** Sorafenib co-crystal structure with VEGFR2 (PDB



1 ID: 4ASD, 2.03 Å). (C) Chemical structure of sunitinib and its depicted binding mode with VEGFR2.  
2 (D) Sunitinib co-crystal structure with VEGFR2 (PDB ID: 4AGD, 2.81 Å). (E) Chemical structure of  
3 axitinib and its depicted binding mode with VEGFR2. (F) Axitinib co-crystal structure with VEGFR2  
4 (PDB ID: 4AG8, 1.95 Å). (G) Chemical structure of nintedanib and its depicted binding mode with  
5 VEGFR2. (H) Nintedanib co-crystal structure with VEGFR2 (PDB ID: 3C7Q, 2.10 Å). (I) Chemical  
6 structure of regorafenib. (J) Chemical structure of pazopanib and its proposed binding mode with  
7 VEGFR2 based on crystal structure of PDB ID: 3CJG (2.25 Å). (K) Chemical structure of lenvatinib  
8 and its depicted binding mode with VEGFR2. Small molecule inhibitors are shown in magenta  
9 backbone, hydrogen bonds are indicated by red dotted lines, and residues that interact with  
10 inhibitors through hydrogen bonds are shown in green backbone.

11 [Figure 8]

12 **Figure 8.** Small molecule kinase inhibitors binding to ALK. (A) Chemical structure of crizotinib and  
13 its depicted binding mode with ALK. (B), (C) Crizotinib co-crystal structure with ALK (PDB ID: 2XP2,  
14 1.9 Å). (D) Chemical structure of ceritinib and its depicted binding mode with ALK. (E), (F) Ceritinib  
15 co-crystal structure with ALK (PDB ID: 4MKC, 2.01 Å). Small molecule inhibitors are shown in  
16 magenta backbone, hydrogen bonds are indicated by red dotted lines, residues that interact with  
17 inhibitors through hydrogen bonds are shown in green backbone, and residues of the DGF motif  
18 are shown in white backbone.

19 [Figure 9]

20 **Figure 9.** Small molecule kinase inhibitors binding to MET. (A) Depicted binding mode of crizotinib  
21 with MET. (B), (C) Crizotinib co-crystal structure with MEK (PDB ID: 2WGJ, 2.0 Å). (D) Chemical

1 structure of cabozantinib. (E) Chemical structure of compound DWF (name derived from PDB  
2 ligand identifier code) and its depicted binding mode with MET. (F, G) Cabozantinib co-crystal  
3 structure with MET (PDB ID: 4MXC, 1.63 Å). Small molecule inhibitors are shown in magenta  
4 backbone, hydrogen bonds are indicated by red dotted lines, residues that interact with inhibitors  
5 through hydrogen bonds are shown in green backbone, and the Asp residue of the DGF motif is  
6 shown in white backbone.

7 [Figure 10]

8 **Figure 10.** Binding mode of irreversible small molecule kinase inhibitors. (A) Chemical structure of  
9 afatinib and its depicted binding mode with EGFR. (B) Afatinib co-crystal structure with wildtype  
10 EGFR (PDB ID: 4G5J, 2.80 Å). (C) Afatinib co-crystal structure with mutant T790M EGFR (PDB ID:  
11 4G5P, 3.17 Å). (D) Chemical structure of ibrutinib and its proposed binding mode with BTK. (E)  
12 Chemical structure of compound B43 and its depicted binding mode with BTK. (F) B43 co-crystal  
13 structure with BTK (PDB ID: 3GEN, 1.60 Å). Wild type and mutant residue790 of EGFR is shown in  
14 yellow backbone, small molecule inhibitors are shown in magenta backbone, hydrogen bonds are  
15 indicated by red dotted lines, residues that interact with inhibitors through hydrogen bonds are  
16 shown in green backbone, covalent bonds are indicated by purple solid lines, and the cysteine  
17 residue contributing to the formation of a covalent bond is shown in purple backbone.

18 [Figure 11]

19 **Figure 11.** Structures of approved small molecule kinase inhibitors binding to serine/threonine  
20 kinase B-Raf. (A) Chemical structure of vemurafenib and its depicted binding mode with mutant  
21 V600E B-Raf kinase. (B) Vemurafenib co-crystal structure with V600E B-Raf (PDB ID: 3OG7, 2.45 Å).

1 (C) Surface show of the vemurafenib-V600E B-Raf complex with the residues of the DFG motif  
2 highlighted in white backbones (PDB ID: 3OG7, 2.45 Å). (D) Chemical structure of dabrafenib. (E)  
3 Chemical structure of the dabrafenib derivative compound 20 and its depicted binding mode with  
4 mutant V600E B-Raf. (F) Compound **20** co-crystal structure with V600E B-Raf (PDB ID: 4CQE, 2.30  
5 Å). (G) Chemical structure of sorafenib and its depicted binding mode with wild type B-Raf. (H)  
6 Sorafenib co-crystal structure with wild type B-Raf (PDB ID: 1UWH, 2.95 Å). (I) Sorafenib co-crystal  
7 structure with mutant V599E B-Raf, mutated residue Glu599 is shown in brown backbone (PDB ID:  
8 1UWJ, 3.5 Å). Small molecule inhibitors are shown in magenta backbone, hydrogen bonds are  
9 indicated by red dotted lines, and residues that interact with inhibitors through hydrogen bonds  
10 are shown in green backbone.

11 [Figure 12]

12 **Figure 12.** MEK kinase inhibitor binding mode. (A) Chemical structure of trametinib. (B) Chemical  
13 structure of Tak-733 and its depicted binding mode with MEK1. (C) Tak-733 co-crystal structure  
14 with MEK1 (PDB ID: 3PP1, 2.70 Å). ATP is shown in cyan backbone, Tak-733 in magenta backbone,  
15 hydrogen bonds are indicated by red dotted lines, and residues that interact with ATP and Tak-733  
16 through hydrogen bonds are shown in green backbone.

17 [Figure 13]

18 **Figure 13.** CDK inhibitor palbociclib. (A) Chemical structure of palbociclib and its depicted binding  
19 mode with CDK6. (B), (C) Palbociclib co-crystal structure with CDK6 (PDB ID: 2EUF, 3.0 Å).  
20 Palbociclib is shown in magenta backbone, hydrogen bonds are indicated by red dotted lines,

1 residues that interact with inhibitors through hydrogen bonds are shown in green backbone, and  
2 residues of the DFG motif are shown in white backbones.

3 [Figure 14]

4 **Figure 14.** PI3K $\delta$  inhibitor idelalisib. (A) Chemical structure of idelalisib and its depicted binding  
5 mode with PI3K $\delta$ . (B), (C) Idelalisib co-crystal structure with PI3K $\delta$  (PDB ID: 4XE0, 2.43 Å). Idelalisib  
6 is shown in magenta backbone, hydrogen bond is indicated by a red dotted line, and residues of  
7 the DFG motif are shown in white backbones.